Citi Maintains a 'Sell' on Cross Country Healthcare (CCRN); Believe Shares Will Continue to Underperform
CCRN Hot Sheet
Rating Summary:1 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Citi maintains a 'Sell' on Cross Country Healthcare Inc (Nasdaq: CCRN). Price target $8.
Citi analyst says, "We expect the shares to underperform over the next 12 months because consensus forward estimates are likely too high and our modest growth estimates don't support a higher 12-month valuation. In other words, the market has not completely discounted the risk of a slowing economy and slowing hospital demand."
Cross Country Healthcare, Inc. (Cross Country) is a provider of healthcare staffing services in the United States, a global provider of clinical trials services to pharmaceutical and biotechnology customers, as well as a provider of other human capital management services focused on healthcare.
Citi analyst says, "We expect the shares to underperform over the next 12 months because consensus forward estimates are likely too high and our modest growth estimates don't support a higher 12-month valuation. In other words, the market has not completely discounted the risk of a slowing economy and slowing hospital demand."
Cross Country Healthcare, Inc. (Cross Country) is a provider of healthcare staffing services in the United States, a global provider of clinical trials services to pharmaceutical and biotechnology customers, as well as a provider of other human capital management services focused on healthcare.
You May Also Be Interested In
- Barclays Cuts Estimates and Price Target on ADP (ADP); Mixed Data From Investor Day
- UBS Maintains a 'Neutral' on VeriFone (PAY); Europe Demand Healthy, but FX Emerges as Headwind
- Canaccord Genuity Maintains a 'Hold' on Tiffany & Co. (TIF); Cutting PT and Estimates
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
